BOPA Position Statement

BOPA supports the withdrawal of histamine 2 (H$_2$) antagonists from paclitaxel pre-medication regimens following publication of research which demonstrates their lack of effect

This position statement replaces the previous publication - BOPA guidance on use of H$_2$ antagonists for hypersensitivity published 5/6/2020.

Following publication of the results of a national research effort coordinated through the BOPA membership, the executive committee is pleased to announce formal support regarding the withdrawal of H$_2$ antagonist components from paclitaxel pre-medication regimens used in clinical practice (1). We would like to thank the pharmacy teams in the 14 participating treatment centres for their support in generating the data required for this study and to members of the BOPA community who helped to produce the final publication.

The findings of this research study are consistent with other recent publications into the effects of H$_2$ antagonists in reducing the incidence and severity of hypersensitivity reactions associated with paclitaxel treatment, and confirm that H$_2$ antagonists confer no additional benefit compared to a combination of an H$_1$ antagonist and corticosteroid (2).

**BOPA therefore endorses UK treatment centres to withdraw H$_2$ antagonists as a component of pre-medication regimens administered before paclitaxel containing regimens.**

Healthcare providers should follow appropriate local/organisational governance procedures prior to implementation.

Following publication of this study, the BOPA executive committee has written to the chair of the MHRA asking for a review of the content of paclitaxel product licenses and requested consideration regarding removal of the requirement to include an H$_2$ component within pre-medication regimens.

**References**

(1) Foreman E, Polwart C, Walker A, Chambers P. Histamine-2 (H$_2$) antagonists can be safely removed from standard paclitaxel premedication regimens. British Journal of Pharmacology. 2022, May: 88(9);4191-4198. DOI: 10.1111/bcp.15363

BOPA Position Statement

Title
H₂ antagonist withdrawal in pre-medication regimens before paclitaxel treatments

Authors/Editors
Andrew Walker

Owner
BOPA Exec Committee

Endorsed by the BOPA exec committee
October 2022

Change History

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Lead Author/Editor</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>June 2020</td>
<td>Fleur Harvey</td>
<td>1st version</td>
</tr>
<tr>
<td>2.0</td>
<td>September 2022</td>
<td>Andrew Walker</td>
<td>Updated to reflect newly published evidence confirming withdrawal of H₂ antagonists</td>
</tr>
</tbody>
</table>

Proposed Target Audience
BOPA members, UKONS, chief pharmacists network, UKCB

Proposed Circulation List
BOPA members, UKONS, chief pharmacists network, UKCB

Contact Details
contact@bopa.org.uk